Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare ultra-long-acting insulin degludec with glargine for efficacy and safety in insulin-naive patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs (OADs). RESEARCH DESIGN AND METHODS: In this 1-year, parallel-group, randomized, open-label, treat-to-target trial, adults with type 2 diabetes with A1C of 7−10% taking OADs were randomized 3:1 to receive once daily degludec or glargine, both with metformin. Insulin was titrated to achieve prebreakfast plasma glucose (PG) of 3.9−4.9 mmol/L. The primary end point was confirmation of noninferiority of degludec to glargine in A1C reduction after 52 weeks in an intent-to-treat analysis. RESULTS: In all, 1,030 participants (mean age 59 years; baseline A1C 8.2%) were randomized (degludec 773, glargine 257). Reduction in A1C with degludec was similar (noninferior) to that with glargine (1.06 vs. 1.19%), with an estimated treatment difference of degludec to glargine of 0.09% (95% CI −0.04 to 0.22). Overall rates of confirmed hypoglycemia (PG <3.1 mmol/L or severe episodes requiring assistance) were similar, with degludec and glargine at 1.52 versus 1.85 episodes/patient-year of exposure (PYE). There were few episodes of nocturnal confirmed hypoglycemia in the overall population, and these occurred at a lower rate with degludec versus glargine (0.25 vs. 0.39 episodes/PYE; P = 0.038). Similar percentages of patients in both groups achieved A1C levels <7% without hypoglycemia. End-of-trial mean daily insulin doses were 0.59 and 0.60 units/kg for degludec and glargine, respectively. Adverse event rates were similar. CONCLUSIONS: Insulins degludec and glargine administered once daily in combination with OADs provided similar long-term glycemic control in insulin-naive patients with type 2 diabetes, with lower rates of nocturnal hypoglycemia with degludec.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All of the phase III trials with IDeg were designed as treat-to-target trials striving for an ambitious (fasting) blood glucose level target of 4–5 mmol/L (70–90 mg/dL).”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a result of the treat-to-target design, a comparison can be made in terms of differences in endpoints such as hypoglycaemia (but not, for example, HbA1c), as illustrated in Table 4 [48–54].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“the concentration of IDeg-specific antibodies and antibodies cross-reacting with IDeg and human insulin was found to be low in studies in patients with T1DM [48, 49] or T2DM [50, 53], indicating that the risk of immunogenicity with IDeg is minimal.”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Ethical principles for medical research involving human subjects
(2003) · Manual for Research Ethics Committees · doi:10.1017/cbo9780511550089.027 · Cited by 2,585
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
(2014) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/jwiet-2014-0117 · Cited by 2,473
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Self-citationHypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794 · cited 1×
“Additionally, the risk, consequences, and fear of hypoglycemia remain a significant limiting factor in intensifying insulin therapy and optimizing glycemic control (9).”
Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects
(2009) · JIBL · doi:10.1515/jibl.2009.12 · Cited by 768
Research works printed but not linked: 2
- International Diabetes foundation. Diabetes atlas 5th edition [article online], 2011. Available from http://www.idf.org/diabetesatlas/5e/the-global-burden. Accessed 10 January 2012
- Heise, 2011, The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state (Abstract), Diabetes, 60, A263
Cited by
Items 201–300 of 342
Hollander, P. A., Kiljanski, J. I., Spaepen, E., & Harris, C. J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13822 · Cited by 7
Rodbard, H. W., Cariou, B., Zinman, B., Handelsman, Y., Wolden, M. L., Rana, A., & Mathieu, C. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12271 · Cited by 7
Self-citationMedium-Term Effects of Insulin Degludec on Patients with Type 1 Diabetes Mellitus
Nakae, R., Kusunoki, Y., Katsuno, T., Tokuda, M., Akagami, T., Murai, K., Hamaguchi, T., Miyagawa, J., & Namba, M. (2014) · Drugs in R&D · doi:10.1007/s40268-014-0048-6 · Cited by 7
Preumont, V., & Buysschaert, M. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.04.007 · Cited by 8
Buchholz, C., Kahle, M., Meier, J. J., & Nauck, M. A. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0972-9700 · Cited by 8
Thammakosol, K., Jantarapootirat, M., Traiwanatham, S., & Sriphrapradang, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70101 · Cited by 6
Monnier, L. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30031-7 · Cited by 6
Lualdi, C., Silverii, G. A., Dicembrini, I., Pala, L., Monami, M., & Mannucci, E. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0920-2 · Cited by 6
Modelling of glucose-insulin dynamics from low sampled data
Aradóttir, T. B., Boiroux, D., Bengtsson, H. L., & Poulsen, N. K. (2018) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2018.09.213 · Cited by 6
Rados, D. R. V., Viecceli, C., Pinto, L. C. F., Gerchman, F., Leitão, C. B., & Gross, J. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-69738-w · Cited by 7
Hamasaki, H. (2013) · Journal of Endocrinology and Metabolism · doi:10.4021/jem193w · Cited by 6
Fadini, G. P., Buzzetti, R., Nicolucci, A., Larosa, M., Rossi, M. C., Cucinotta, D., On behalf of the RESTORE-2 Study Group, Gabellieri, E., Alberto, M., Pagotto, U., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01925-9 · Cited by 7
Osonoi, T., Onishi, Y., Nishida, T., Hyllested-Winge, J. L., & Iwamoto, Y. (2015) · Diabetology International · doi:10.1007/s13340-015-0221-3 · Cited by 6
Kerlan, V., Gouet, D., Marre, M., & Renard, É. (2013) · Annales d Endocrinologie · doi:10.1016/j.ando.2013.04.004 · Cited by 6
Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data
Kaku, K., Wolden, M. L., Hyllested-Winge, J. L., & Nørtoft, E. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0225-z · Cited by 6
Hamamoto, Y., Honjo, S., Fujimoto, K., Tokumoto, S., Ikeda, H., Wada, Y., & Koshiyama, H. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0541-0 · Cited by 6
VISENTIN, R., Schiavon, M., & Man, C. D. (2020) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc44109.2020.9175271 · Cited by 7
Modern basal insulin analogs: An incomplete story
Singh, A. K., & Gangopadhyay, K. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.140239 · Cited by 6
Madhu, S., & Velmurugan, M. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.109690 · Cited by 6
Builes-Montaño, C. E., Wandurraga-Sánchez, E. A., Ramírez, Á., & Ordóñez, J. E. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01471-9 · Cited by 5
Li, Y., Kar, S., Li, C., Liu, M. R., Luan, Z., Yuan, G., Zhong, X., & Mu, Y. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01701-2 · Cited by 5
Kalra, S. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0235-x · Cited by 5
Préparations insuliniques au cours de la dernière décennie.
Monnier, L., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30034-8 · Cited by 5
Les analogues lents de l’insuline : une aide pour l’insulinothérapie des sujets âgés
Bauduceau, B., Bordier, L., & Doucet, J. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70803-x · Cited by 5
Ghosal, S., Sinha, B., & Gangopadhyay, K. K. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s63878 · Cited by 6
Kaku, K., & Eid, M. A. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12348 · Cited by 5
Clinical and cost–effectiveness of insulin degludec: from clinical trials to clinical practice
Evans, M., & McEwan, P. C. (2015) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.15.10 · Cited by 5
Échec des antidiabétiques oraux à doses maximales tolérées : Quels traitements injectables?
Monnier, L., & Colette, C. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30030-x · Cited by 6
Luo, Y., Xia, J., Zhao, Z., Chang, Y., Bee, Y. M., Nguyen, K. T., Lim, S. K., Yabe, D., McGill, M. J., Kong, A. P. S., et al. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13381 · Cited by 6
Diabetes Mellitus in the Next Decade: Novel Pipeline Medications to Treat Hyperglycemia
Fonseca, V. A. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.04.007 · Cited by 5
Weatherall, J., Bloudek, L. M., & Buchs, S. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1251893 · Cited by 6
Ragonese, M., Larosa, M., Angotti, S., Annese, S., Cruciani, L., Dainelli, M., Lucisano, G., Prosperini, G., Sacco, M., Salomone, E., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00902-1 · Cited by 5
Basal Insulin Inadequacy versus Failure – Using Appropriate Terminology
Kalra, S., & Gupta, Y. (2015) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2015.11.02.79 · Cited by 5
Bonet, J., VISENTIN, R., & Man, C. D. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241245930 · Cited by 5
Ji, L., Luo, Y., Bee, Y. M., Xia, J., Nguyen, K. T., Zhao, W., Chen, L., Chan, S. P., Deerochanawong, C., Lim, S. K., et al. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13392 · Cited by 5
Advances in Basal Insulin Therapy
Goldman, J. D., & White, J. R. (2016) · Journal of Pharmacy Technology · doi:10.1177/8755122516667128 · Cited by 4
THERAPY OF TYPE 2 DIABETES MELLITUS IN ELDERLY PATIENTS: RISKS AND PROSPECTS
Morgunov, L. Y. (2017) · Research and Practical Medicine Journal · doi:10.17709/2409-2231-2017-4-4-12 · Cited by 5
A general view of epidemiology of hypoglycemia in type 1 and type 2 diabetes mellitus
Brož, J., & Urbanová, J. (2019) · Vnitřní lékařství · doi:10.36290/vnl.2019.050 · Cited by 5
The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes
Strain, W. D., Morgan, A. R., & Evans, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01162-3 · Cited by 4
Kesavadev, J., Murthy, L. S., Chaudhury, T., Yalamanchi, S. R., Giri, J., Gupta, S., Phatak, S., Modi, K. D., Chatterjee, S., Manjunath, A., et al. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100184 · Cited by 4
Estimating a Personalized Basal Insulin Dose from Short-Term Closed-Loop Data in Type 2 Diabetes
Engell, S. E., Aradóttir, T. B., Ritschel, T. K. S., Bengtsson, H. L., & Jørgensen, J. B. (2022) · IEEE Conference on Decision and Control (CDC) · doi:10.1109/cdc51059.2022.9992960 · Cited by 4
Novel and Emerging Insulin Preparations for Type 2 Diabetes
Cheung, K. K. T., & Senior, P. A. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.082 · Cited by 4
Nardi, E., Prastaro, M., Santoro, C., Gallo, L., Simeoli, L., Fontanarosa, S., Paolillo, S., Gargiulo, P., Esposito, G., & Filardi, P. P. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104033 · Cited by 3
Shestakova, M. V., Antciferov, M. V., Mayorov, A. Y., Ruyatkina, L. A., Суплотова, Л. А., Dogadin, S. A., Lebedev, N. B., & Alekseeva, Y. G. (2015) · Diabetes Mellitus · doi:10.14341/dm7694 · Cited by 5
Higher concentration insulins: an overview of clinical considerations
Reid, T., Schafer, F., & Brusko, C. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1325311 · Cited by 3
Muñoz‐Torres, M. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2013.03.012 · Cited by 3
Sethi, B. K., Unnikrishnan, A., Ayyar, V. S., Jabbar, P. K., Ganguly, K. K., Bhandari, S., Rastogi, A., Mukherjee, R., Sundaram, V., & Asirvatham, A. R. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01284-2 · Cited by 3
de Adana, M. S. R., Domínguez, M., Morillas, V., Colomo, N., Mora, M. R. V., Guerrero, M., García‐Escobar, E., Carreira, M., Romero‐Zerbo, S., Linares, F., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110238 · Cited by 3
Ponomareva, E., Schmerold, L. M., Srinivas, S. S. S., Preblick, R., Park, S., Wilson, L., & Revel, A. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2277058 · Cited by 3
Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus
Kang, S., Ahn, Y., Oh, T. K., Lee, W., Chun, S. W., Bae, B., Dahaoui, A., Jeong, J. S., Jung, S.-E., & Jang, H. C. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0297 · Cited by 3
Wang, W., Chang, X., Lehrskov, L. L., Li, L., Nordentoft, M., Quan, J., Sha, Y., Zhong, X., Yang, C., & Zhu, D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01533-6 · Cited by 3
The vexed question of hypoglycaemia and health economics
Home, P. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12266 · Cited by 3
Muñoz‐Torres, M. (2014) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2014.02.010 · Cited by 4
Number-Based Approach to Insulin Taxonomy
Kalra, S., & Gupta, Y. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0129-8 · Cited by 3
Vedtofte, L., Knop, F. K., & Vilsbøll, T. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1029455 · Cited by 3
Røder, M. E. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1043270 · Cited by 3
Griffin, T. P., & Dinneen, S. F. (2021) · Annals of Internal Medicine · doi:10.7326/acpj202103160-034 · Cited by 3
Expanded Basal Insulin Options for Type 2 Diabetes Mellitus
Olin, J. L., & Harris, K. B. (2016) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2016.07.011 · Cited by 2
Efficacy, safety and clinical use of newer basal insulins analogs
Neto, A. M., & Ferrari, M. T. M. (2018) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2018.06.00178 · Cited by 2
Li, T., Liu, H., Li, S., Yu, H., Li, J., Tan, H., & Yu, Y. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01207-1 · Cited by 3
United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
Rendell, M. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s132581 · Cited by 3
Insulin degludec – The impact of a new basal insulin on care in type 2 diabetes
Khunti, K., Cos, X., & Rutten, G. E. H. M. (2013) · Primary care diabetes · doi:10.1016/j.pcd.2013.09.003 · Cited by 2
Characteristics and practicalities of a new basal insulin
Stockley, S. (2014) · British Journal of Nursing · doi:10.12968/bjon.2014.23.1.16 · Cited by 2
Insulin degludec and insulin degludec/insulin aspart: a guide to their use in diabetes mellitus
Keating, G. M. (2013) · Drugs & Therapy Perspectives · doi:10.1007/s40267-013-0073-5 · Cited by 2
Thurston, M. M., Galdo, J. A., & Bourg, C. A. (2015) · Clinical Diabetes · doi:10.2337/diaclin.33.1.20 · Cited by 2
Crasto, W., Jarvis, J., & Davies, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-10939-8_2 · Cited by 2
Hirose, T., Cai, Z., Yeo, K. P., Imori, M., Ohwaki, K., & Imaoka, T. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12667 · Cited by 2
Aradóttir, T. B., Boiroux, D., Bengtsson, H. L., Jørgensen, J. B., & Poulsen, N. K. (2019) · IEEE Conference on Control Technology and Applications (CCTA) · doi:10.1109/ccta.2019.8920633 · Cited by 2
Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c.
Chung, J. W., Hartzler, M. L., Smith, A. A., Hatton, J., & Kelley, K. W. (2018) · Europe PMC (PubMed Central) · Cited by 5
Nakanishi, S., Shimoda, M., Tatsumi, F., Kohara, K., Obata, A., Sanada, J., Fushimi, Y., Anno, T., Kawasaki, F., Mune, T., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01077-z · Cited by 2
Vargas‐Uricoechea, H., & Frías, J. P. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.04.014 · Cited by 2
Duman, T. T., Aktaş, G., Tel, B. M. A., Bilgin, S., Kahveci, G., & Kurtkulağı, Ö. (2022) · Journal of Public Health · doi:10.1007/s10389-022-01769-1 · Cited by 2
Sawamura, T., Karashima, S., Ohbatake, A., Higashitani, T., Ohmori, A., Sawada, K., Yamamoto, R., Kometani, M., Katsuda, Y., & Yoneda, T. (2024) · Medicina · doi:10.3390/medicina60030450 · Cited by 1
Umpierrez, G. E., Pogge, E. K., Li, X., Preblick, R., Gill, J., & Pandya, N. (2025) · Journal of health economics and outcomes research · doi:10.36469/001c.133274 · Cited by 1
Mohebbi, A., Kjøller, N.-K., Johansen, A. R., Bengtsson, H. L., Jensen, M. L., Stallknecht, B. M., & Mørup, M. (2025) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc58623.2025.11253142 · Cited by 1
Insulin degludec + liraglutide: a complementary combination
Stinkens, K., Peene, B., & Mathieu, C. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1217328 · Cited by 3
Self-citationUltra-long acting insulin versus long-acting insulin for type 1 diabetes mellitus
Ooi, C. P., Ting, T. H., & Loke, S. C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011102 · Cited by 1
RetractedInsuline dégludec : mode d’action et profil pharmacocinétique
Cariou, B. (2013) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(13)70565-0 · Cited by 3
Self-citationDiabetes clinical decision-making in patients at risk: Taking patient complexity into account
Lavernia, F. (2013) · Osteopathic Family Physician · doi:10.1016/j.osfp.2012.11.003 · Cited by 1
Efficacy without barriers to insulin therapy: lessons from the BEGIN trial programme.
Mithal, A., Kumar, A., Jain, S. M., & Kumar, H. (2014) · PubMed · Cited by 1
Degludec: a long-duration insulin
Alexanderson-Rosas, E. G., Llamas-Moreno, J. F., Castro-Martínez, M. G., Frenk-Barón, P., Romo-Pérez, O. A., & Mena-Madrazo, J. A. (2015) · Medicina Interna de México · Cited by 2
Račická, E. (2017) · Interní medicína pro praxi · doi:10.36290/int.2017.012 · Cited by 2
Randomised Controlled Trials in Diabetes Research: A Pathway to Interpreting Published Results
Battelino, T., & Mauricio, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01143-6 · Cited by 1
▼Insulin degludec for diabetes mellitus
(2013) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2013.7.0190 · Cited by 1
Wolters, J., Wollenhaupt, D., Aziz, M. S. A. E., & Nauck, M. A. (2022) · Journal of Diabetes Research · doi:10.1155/2022/4758042 · Cited by 1
Altay, F. P., Farzaliyeva, A., İyidir, Ö. T., Bozkuş, Y., Kirnap, N. G., Kut, A., Nar, A., & Tütüncü, N. B. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666221124112413 · Cited by 1
Nedogoda, S. V., Barykina, I. N., Salasyuk, A. S., Lutova, V. O., & Popova, E. A. (2022) · Diabetes Mellitus · doi:10.14341/dm12774 · Cited by 1
Zúñiga, C., & Machado‐Duque, M. E. (2023) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.10.4.810 · Cited by 1
Hasnani, D., Jha, S., Saboo, B., Prasanna, P. L., Sanghvi, A., Sowani, A., & Chavda, V. (2024) · Clinical Diabetology · doi:10.5603/cd.98892 · Cited by 1
Ji, L., Gao, L., Cheng, Z., Ma, G., Li, S., Wang, H., Liu, J., Lu, Y., Liu, M., Geng, J., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2401096 · Cited by 1
Kamrul-Hasan, A. B. M., Borozan, S., Fernandez, C. J., Dutta, D., Nagendra, L., & Pappachan, J. M. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0716 · Cited by 1
Ampudia‐Blasco, F. J. (2013) · Avances en Diabetología · doi:10.1016/j.avdiab.2013.10.001 · Cited by 2
Cariou, B. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70806-5
Self-citationMeece, J. D., Pearson, T. L., & Siminerio, L. M. (2014) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721714527802
Recent advances with insulin degludec for the treatment of Type 2 diabetes
Stokes, V. J., & Gough, S. C. L. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.917045
Insulin degludec — ein neues Basalinsulin zur Behandlung von Typ-1- und Typ-2-Diabetes
Gallwitz, B., & Haak, T. (2013) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-013-2186-0 · Cited by 1
New treatments for type 2 diabetes: are we any closer to reducing iatrogenic hypoglycaemia?
Seewoodhary, J., Wong, S. P. Y., & Ekanayake, K. P. (2015) · Practical Diabetes · doi:10.1002/pdi.1977
Stümvoll, M., & Scherbaum, W. A. (2015) · Der Diabetologe · doi:10.1007/s11428-015-1344-7
Understanding the safety of the new ultra long acting basal insulin.
Ramachandran, A., Gupta, V., Kesavadev, J., & Kalra, S. (2014) · PubMed
Суплотова, Л. А., Плотников, Н. В., Романова, Н. В., Бельчикова, Л. Н., Khieva, E. V., & Shestakova, M. V. (2015) · Diabetes Mellitus · doi:10.14341/dm7695
Metadata
- Authors
- Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators
- Affiliations
- Mount Sinai Hospital (CA)
- Scripps Whittier Diabetes Institute, La Jolla, California
- Centre Hospitalier Universitaire de Nantes (FR)
- Metabolic Institute of America, Tarzana, California
- Endocrine and Metabolic Consultants, Rockville, Maryland
- Novo Nordisk (Denmark) (DK)
- Universitair Ziekenhuis Leuven (BE)
- Corresponding author
- Mathieu, Chantal
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-11-14
- Volume
- 35
- Issue
- 12
- Pages
- 2464-2471
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3507614
- OpenAlex
- W1965832529
- Semantic Scholar
- d71056ccc92e22c6deda4b52fb5b27aada6b0588
- Cited by
- 336
- References
- 34
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 12 · 2023: 15 · 2022: 16 · 2021: 13 · 2020: 17 · 2019: 29 · 2018: 32 · 2017: 38 · 2016: 30 · 2015: 41 · 2014: 42 · 2013: 35 · 2012: 4
- FWCI
- 31.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Amarin Corporation
- MannKind Corporation
- Halozyme
- Novo Nordisk
- Genentech
- Merck Sharp and Dohme
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin degludec, insulin glargine, type 2 diabetes, insulin-naive patients, ultra-long-acting insulin, glycemic control, HbA1c, hypoglycemia, nocturnal hypoglycemia, metformin, oral antidiabetic drugs, insulin dose, non-inferiority, treat-to-target, insulin dose adjustment, adverse events
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Treatment Outcome, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.